Advantages of using saquinavir to treat HIV infection

Abstract

The protease inhibitor saquinavir is a prime candidate for use as initial therapy in treatment-naive patients with HIV infection due to its low potential for cross resistance with other protease inhibitors. Recent study results demonstrating the agent’s efficacy in both treatment-naive and pretreated patients with HIV infection were presented at the Saquinavir European launch meeting [ Montreux, Switzerland; September 1996 ], which was sponsored by F. Hoffmann-La Roche.